Benjamin Graham Detailed Fundamental Analysis

Validea's guru fundamental report indicates that Regeneron Pharmaceuticals (REGN) receives a 71% rating based on their 'Value Investor' model, which is based on the investment strategy of Benjamin Graham. The model favors the company due to strong performance in sales, current ratio, low long-term debt, and long-term EPS growth, but flags the stock for high P/E and Price/Book ratios. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Analysis

Validea's fundamental report on Regeneron Pharmaceuticals Inc. (REGN), utilizing a 'Value Investor' model based on Benjamin Graham's deep value strategy, assigned the company a 71% rating. This score, while indicating several fundamental strengths, falls short of the 80% threshold that typically signals strategy interest. REGN successfully met criteria related to its sector, sales performance, current ratio, manageable long-term debt relative to net current assets, and consistent long-term EPS growth. Conversely, the company failed on crucial valuation metrics inherent to Graham's approach, specifically its P/E ratio and Price/Book ratio, which the strategy seeks to be low. As a large-cap growth stock within the Biotechnology & Drugs industry, REGN's higher valuation multiples may inherently contrast with the stringent requirements of this deep value screen, despite its positive underlying business fundamentals.

Key Decisions for Investors

• Investors should acknowledge REGN's demonstrated strengths in operational and financial fundamentals, including robust sales, a healthy current ratio, low long-term debt, and positive long-term EPS growth trends.
• Given that REGN's 71% score on the Graham-based value model is below the 80% interest threshold due to failing P/E and Price/Book ratio tests, investors should carefully consider if its growth stock profile justifies these higher valuation metrics.
• It may be prudent to supplement this value-centric analysis with growth-oriented investment models to form a comprehensive view, particularly for a stock identified as a 'large-cap growth stock' in the biotechnology sector.